Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04975997 · ClinicalTrials.gov registry record · Phase 3
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 study of Multiple Myeloma, sponsored by Celgene.
- Active
- Registry status
- Phase 3
- Development phase
- 864
- Enrollment target
- 20
- Study locations
NCT04975997 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by Celgene. The registered enrollment target is 864 participants, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (59% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT04975997, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Celgene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 864 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Daratumumab
- DRUG Iberdomide
- DRUG Bortezomib
Study Locations (20)
Florida
- Local Institution - 029 - Fort Myers
- Local Institution - 693 - Ocala
- Local Institution - 028 - St. Petersburg
- Local Institution - 045 - Tamarac
- Local Institution - 034 - West Palm Beach
- Local Institution - 685 - Weston
California
- Local Institution - 641 - Cerritos
- Local Institution - 681 - Fountain Valley
- Local Institution - 047 - Los Angeles
- Local Institution - 684 - Newport
Louisiana
- Local Institution - 041 - Alexandria
- Local Institution - 682 - Baton Rouge
- Local Institution - 027 - Baton Rouge
Arkansas
- Local Institution - 035 - Hot Springs
Connecticut
- Local Institution - 033 - New Haven
Georgia
- Local Institution - 018 - Atlanta
Illinois
- Local Institution - 640 - Elk Grove Village
Indiana
- Local Institution - 697 - Dyer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 864 participants |
| Start Date | 2022-06-23 |
| Est. Completion | 2032-06-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04975997
The ClinicalTrials.gov registry entry for NCT04975997 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 864 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 545-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (59% higher). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.
NCT04975997 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT04975997 about?
NCT04975997 is a clinical study titled "Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)". This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple ...
What is the current status of trial NCT04975997?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 864 participants. The study started on 2022-06-23. Estimated completion is 2032-06-25.
What conditions does trial NCT04975997 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04975997?
The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Iberdomide (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT04975997?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04975997 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.